Atopic Dermatitis

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

LC-OCT provided quick, noninvasive assessment of skin conditions with detailed imaging aids diagnosis and treatment, especially for patients with darker skin types.

Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.

Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.

Dermatology experts evaluate topical ruxolitinib cream's effectiveness in rapidly relieving itch and offer guidance on its black box warning. They also discuss its efficacy in children under 2, highlighting its suitability for those with tactile sensitivity.

Dr James Del Rosso underscores the importance of phase 2 and dose-ranging studies to uncover efficacy differences between therapies, while the panel explores how clinical data from ruxolitinib trials mirrors real-world outcomes.

James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.

Researchers noted that further examination and monitoring for headache disorders in patients with atopic dermatitis may be warranted.

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.

Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.

Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.

Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a recent study.

Ruth Ann Vleugels, MD, MPH, MBA, delves into patient-specific considerations and action plans when on a JAK inhibitor, including shingles prevention and management.

Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.

Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.

Ruth Ann Vleugels, MD, MPH, MBA, shares insights that she gives her own residents on JAK inhibitor selection, risks, benefits, and data available.